Vibrio cholerae ParE2 poisons DNA gyrase via a mechanism distinct from other gyrase inhibitors.

TitleVibrio cholerae ParE2 poisons DNA gyrase via a mechanism distinct from other gyrase inhibitors.
Publication TypeJournal Article
Year of Publication2010
AuthorsYuan, J., Y. Sterckx, L. A. Mitchenall, A. Maxwell, R. Loris, and M. K. Waldor
JournalJ Biol Chem
Volume285
Issue51
Pagination40397-408
Date Published2010 Dec 17
Type of Articleta
ISSN1083-351X
KeywordsBacterial Proteins, DNA Gyrase, DNA, Bacterial, DNA, Superhelical, DNA-Binding Proteins, Enzyme Inhibitors, Escherichia coli, Escherichia coli Proteins, Genetic Loci, Humans, Plasmids, Vibrio cholerae
Abstract

DNA gyrase is an essential bacterial enzyme required for the maintenance of chromosomal DNA topology. This enzyme is the target of several protein toxins encoded in toxin-antitoxin (TA) loci as well as of man-made antibiotics such as quinolones. The genome of Vibrio cholerae, the cause of cholera, contains three putative TA loci that exhibit modest similarity to the RK2 plasmid-borne parDE TA locus, which is thought to target gyrase although its mechanism of action is uncharacterized. Here we investigated the V. cholerae parDE2 locus. We found that this locus encodes a functional proteic TA pair that is active in Escherichia coli as well as V. cholerae. ParD2 co-purified with ParE2 and interacted with it directly. Unlike many other antitoxins, ParD2 could prevent but not reverse ParE2 toxicity. ParE2, like the unrelated F-encoded toxin CcdB and quinolones, targeted the GyrA subunit and stalled the DNA-gyrase cleavage complex. However, in contrast to other gyrase poisons, ParE2 toxicity required ATP, and it interfered with gyrase-dependent DNA supercoiling but not DNA relaxation. ParE2 did not bind GyrA fragments bound by CcdB and quinolones, and a set of strains resistant to a variety of known gyrase inhibitors all exhibited sensitivity to ParE2. Together, our findings suggest that ParE2 and presumably its many plasmid- and chromosome-encoded homologues inhibit gyrase in a different manner than previously described agents.

DOI10.1074/jbc.M110.138776
Alternate JournalJ. Biol. Chem.
PubMed ID20952390
PubMed Central IDPMC3001019
Grant ListR37 AI-42347 / AI / NIAID NIH HHS / United States
/ / Biotechnology and Biological Sciences Research Council / United Kingdom
/ / Howard Hughes Medical Institute / United States